MedTrace Logo

The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum

NCT03010072 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-07-22

No results posted yet for this study

Summary

This is a single-center, prospective, open-label, controlled, randomized, cross-over study in 34 prevalent end-stage renal disease patients on chronic hemodialysis treatment with hyperphosphatemia.

Conditions

  • Endstage Renal Disease

Interventions

DRUG

low-dose sucroferric oxyhydroxide

250 mg suroferric oxyhydroxide

DRUG

high-dose sucroferric oxyhydroxide

2000 mg suroferric oxyhydroxide

Sponsors & Collaborators

  • Vifor Fresenius Medical Care Renal Pharma

    collaborator INDUSTRY

  • Prim. Priv. Doz. Dr. Daniel Cejka

    lead OTHER

Principal Investigators

  • Daniel Cejka, Dr. · Sponsor/PI

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-09
Primary Completion
2018-12-31
Completion
2019-05-10

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03010072 on ClinicalTrials.gov